Redbiotec sells CMV program to Pfizer Schlieren, Zurich, Switzerland[removed]Privately held Swiss Biopharmaceutical Company Redbiotec based in Zurich-Schlieren recently announced that it has sold Redvax GmbH, a spin-of

First Page		Document Content
Date: 2015-01-11 09:20:52 Pfizer Cytomegalovirus vaccine Viral diseases Zurich Cantonal Bank Human cytomegalovirus Medicine Health Biology Vaccines Corporate crime Dow Jones Industrial Average		Redbiotec sells CMV program to Pfizer Schlieren, Zurich, Switzerland[removed]Privately held Swiss Biopharmaceutical Company Redbiotec based in Zurich-Schlieren recently announced that it has sold Redvax GmbH, a spin-of Add to Reading List Source URL: www.redbiotec.ch Download Document from Source Website File Size: 179,49 KB Share Document on Facebook

	巴斯德讲坛-资深系列 Pasteur ColloquiumSenior New vaccine strategies using cytomegalovirus [Speaker] Prof. Klaus Frueh [Time] DocID: 1tTUl - View Document
	American Journal of Epidemiology ª The AuthorPublished by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e-mail: journals.pe DocID: 1q7lY - View Document
	Press release Redbiotec and TeselaGen to Partner on Herpesvirus vaccine library Zurich, Switzerland and San Francisco, CA, August 28, 2013 Redbiotec and TeselaGen have announced a joint venture to build a scalable, integ DocID: 1n9sg - View Document
	NATIONAL FOREARLY HEARING ASSESSMENT A RESOURCECENTER DocID: 18Ake - View Document
	Study announces a durable vaccine for Ebola DocID: 10S66 - View Document